New York, NY, February 1, 2005 – Infinity Capital Group, Inc, announced today that it has signed a merger and investment term sheet with Medico Labs, Inc., a privately held, Hamilton, NJ, based pharmaceutical company with approximately $4.1 million in revenue in 2004. The term sheet provides that Medico will be merged with Satellite Organizing Solutions, Inc. (Pink Sheets: SOZG), a Portfolio Company of Infinity Capital. Medico and Satellite have entered into a binding letter of intent subject to due diligence review, entering into a formal Merger Agreement and obtaining the consent of Medico’s lenders. As a result of the proposed transaction, Medico will be merged into Satellite, or a wholly owned subsidiary of Satellite, which will change its name to Medico Labs, Inc. upon completion of the merger. Medico’s existing management team will manage the day to day operations of the merged company. Medico shareholders will receive 14,029,000 shares of Satellite common stock in the merger. An additional 5,110,000 shares will be issued to Medico shareholders in escrow. Infinity has agreed to use its best efforts to make a $1,000,000 minimum investment in Medico in the form of a two year convertible note by April 30, 2005 and to provide Medico with bridge financing of $250,000 on the date that the merger is completed. If Infinity completes the $1,000,000 investment by April 30, 2005, the 5,110,000 escrow shares will be cancelled and returned to treasury. The proposed investment will be made at a pre-money valuation of $19.3 million and is based upon 19,289,500 fully diluted shares of Medico post-merger.

About Medico Labs, Inc.

Medico Labs, Inc., (http://www.medicolabsinc.com) is a manufacturer of store brand over-the-counter (OTC) pharmaceutical and nutritional products, and was founded to serve the store brand retailers, private label wholesalers, contract distributors of OTC pharmaceuticals in USA and abroad, with liquid dose OTC medicines as well as liquid and solid dose dietary supplements & nutraceuticals. The Company sells over 25 private/ store brand products and 35 brand name products under the Medibest label, that are categorized as analgesics, cough/cold/allergy/sinus, gastrointestinal and vitamins/ nutritional supplements/diet aids. Medico target markets include local, national and international contract & private label distributors, store brand drug retail chain stores, food distribution chain stores & warehouses, convenience store chains, drug wholesalers & exporters.

Medico is currently embarking on R&D for follow-on or next generation DESI & ANDA prescription products in liquid as well as solid doses. Medico has developed and applied for a patent on the formulation of an immune enhancing nutritional formula, which, according to preliminary reports, is beneficial against HIV disease. In addition the Company is working on nutritional supplement formulations for controlling blood sugar in Type II diabetic cases, as well as potentially developing ANDAs for generic drug products like Zoloft®, Paxil®, Prozac®.

About Infinity Capital Group, Inc.

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995:

The statements contained in this news release include certain predictions and projections that may be considered forward-looking statements under securities law. These statements involve a number of important risks and uncertainties that could cause actual results to differ materially including, but not limited to, the performance of the merged companies, as well as other economic, competitive and technological factors involving the merged company's operations, markets, services, products and prices. The matters discussed in this news release are forward-looking statements involving risks and uncertainties that could cause actual results to differ materially from those in such forward-looking statements. Potential risks and uncertainties include, but are not limited to, SOZG's extremely limited operating history, uncertainties related to the merged company's access to additional capital, the ability of the merged company to obtain patents and regulatory approvals for its products, the ability of the merged company to enter into contracts with new customers, competition and dependence on key management.